Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal dose for topical use of tranexamic acid after cardiovascular surgery
KCT0004211Phase 4Withdrawn
- Sponsor
- Korea University Anam Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tranexamic acid in heart failure (HF), myocardial infarction (MI), angina pectoris, coronary arteriosclerosis, arrhythmia, sponsored by Korea University Anam Hospital. Planned start Jan 2023; status: withdrawn.
02
Drugs
tranexamic acid
03
Conditions
heart failure (HF)myocardial infarction (MI)angina pectoriscoronary arteriosclerosisarrhythmia
Beyond the preview
Go deeper on KCT0004211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004211.